<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367391</url>
  </required_header>
  <id_info>
    <org_study_id>41720</org_study_id>
    <nct_id>NCT02367391</nct_id>
  </id_info>
  <brief_title>Penn State TXT2Quit Study</brief_title>
  <official_title>Pilot Randomized Trial of an Automated Smoking Cessation Intervention Via Mobile Phone Text Messages as an Adjunct to Varenicline in Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the feasibility and short term smoking cessation outcomes of an
      automated smoking cessation intervention delivered via mobile phone text messaging as an
      adjunct to Varenicline in a primary care setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Point Prevalence of 7-day Tobacco Abstinence Biochemically Validated by Exhaled CO &lt; 10ppm at Visit 3 (12 Weeks After Target Quit Day)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Abstinence at the 12-week Follow up</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days of Varenicline Use</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Active Smoking Cessation Activities Used</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of activities completed out of 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous Lapse-free Tobacco Abstinence From 4 Weeks to 12 Weeks, Biochemically Validated at Visit 2 and Visit 3.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in Days) to Relapse After the Target Quit Day</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score on the Positive Smoking Cessation Activities Measure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total score for 6 items (scored 0-3). Total score range 0-18.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Nicotine Dependence, Cigarettes</condition>
  <arm_group>
    <arm_group_label>Motivational Text Messages</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Text Messages</intervention_name>
    <description>Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
    <arm_group_label>Motivational Text Messages</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Usual Care. All participants receive the active medication, Varenicline.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoke &gt;4 cigarettes/day for at least 6 months

          -  Age 21+

          -  Want to quit and ready to try in next 30 days

          -  Willing to quit all forms of tobacco (including e-cigs)

          -  Willing to use Chantix to try to quit

          -  Have a cell phone able to receive text messages

          -  Willing to attend 3 visits and use varenicline for smoking cessation

          -  Plan to live in local area for next 6 months

          -  Read and write in English

          -  Women not pregnant and taking steps to avoid

          -  Able to understand and willing to sign consent

        Exclusion Criteria:

          -  History of allergic reaction or other adverse event while using varenicline

          -  Used a smoking cessation aid/medicine in past 1 month (including e-cigs)

          -  Currently pregnant or nursing

          -  Does not have a mobile phone that can send and receive text messages or unwilling to
             receive study texts

          -  Uncontrolled serious mental illness or substance abuse or inpatient treatment for
             these in the past 6 months

          -  Uses non-cigarette tobacco products and does not plan to quit all tobacco.

          -  Has a history of kidney problems or receives dialysis

          -  Had any thoughts that they would be better off dead or of deliberate self-harm in the
             prior 4 weeks

          -  Had a heart attack in the past 4 weeks

          -  Mental conditions that would prohibit the participant from completing the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2017</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Foulds</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Motivational Text Messages</title>
          <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Motivational Text Messages</title>
          <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="12.3"/>
                    <measurement group_id="B2" value="44.5" spread="11.6"/>
                    <measurement group_id="B3" value="45.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence of 7-day Tobacco Abstinence Biochemically Validated by Exhaled CO &lt; 10ppm at Visit 3 (12 Weeks After Target Quit Day)</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence of 7-day Tobacco Abstinence Biochemically Validated by Exhaled CO &lt; 10ppm at Visit 3 (12 Weeks After Target Quit Day)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sustained Abstinence at the 12-week Follow up</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Abstinence at the 12-week Follow up</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days of Varenicline Use</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Varenicline Use</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="37.2"/>
                    <measurement group_id="O2" value="55.7" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Active Smoking Cessation Activities Used</title>
        <description>Number of activities completed out of 6</description>
        <time_frame>12 weeks</time_frame>
        <population>This data is presented for only participants who showed to Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Active Smoking Cessation Activities Used</title>
          <description>Number of activities completed out of 6</description>
          <population>This data is presented for only participants who showed to Visit 2.</population>
          <units>activities</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.3"/>
                    <measurement group_id="O2" value="4.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Lapse-free Tobacco Abstinence From 4 Weeks to 12 Weeks, Biochemically Validated at Visit 2 and Visit 3.</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Lapse-free Tobacco Abstinence From 4 Weeks to 12 Weeks, Biochemically Validated at Visit 2 and Visit 3.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (in Days) to Relapse After the Target Quit Day</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Time (in Days) to Relapse After the Target Quit Day</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="28.9"/>
                    <measurement group_id="O2" value="16.5" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score on the Positive Smoking Cessation Activities Measure</title>
        <description>Total score for 6 items (scored 0-3). Total score range 0-18.</description>
        <time_frame>12 weeks</time_frame>
        <population>This data is presented for only participants who showed to Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Motivational Text Messages</title>
            <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score on the Positive Smoking Cessation Activities Measure</title>
          <description>Total score for 6 items (scored 0-3). Total score range 0-18.</description>
          <population>This data is presented for only participants who showed to Visit 2.</population>
          <units>activities</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="3.8"/>
                    <measurement group_id="O2" value="9.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Motivational Text Messages</title>
          <description>Motivational Text Messages: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Control: Usual Care. All participants receive the active medication, Varenicline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Development of Diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Balance Problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increased mucus production in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Increased Salivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Coughing up blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraines</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Vivid or Unusual Dreams</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nicotine Withdrawal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Thoughts of death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Skin Peeling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Drug/Alcohol Rehab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Coordinator</name_or_title>
      <organization>Penn State College of Medicine</organization>
      <phone>7175310003 ext 289511</phone>
      <email>jyingst@phs.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

